BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
BCNU is an effective antitumor agent in the treatment of Hodgkin's disease. Forty-seven percent of a group of patients with advanced disease, refractory to combination or sequential-agent chemotherapy, achieved an objective response to BCNU. Bone marrow toxicity was delayed in onset and was dose related. When incorporated into a maintenance program after remission induction with combination chemotherapy, BCNU appeared to delay, but not ultimately prevent, relapses during a 2-year followup period. Toxic effects associated with BCNU maintenance therapy in this clinical situation were significantly greater than toxic effects associated with no maintenance therapy.